HCA
URGN icon

Horan Capital Advisors’s UroGen Pharma URGN Stock Holding History

Horan Capital Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$33K – 239
2019
Q4 		$33K Hold
1,000
– – 0.02% 167
2019
Q3 		$24K Buy
+1,000
New +$32.7K 0.01% 190

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Horan Capital Advisors's URGN Position: Q1 2020 in Review

Horan Capital Advisors sold out of UroGen Pharma (URGN) in Q1 2020, closing a stake of 1,000 shares — an estimated $33K sold.

Horan Capital Advisors first reported a position in URGN in Q3 2019 and held it in 2 quarters. The position peaked at $33K in Q4 2019. 79 funds tracked by Wall St. Rank hold URGN as of Q1 2020.

  • Horan Capital Advisors reported no remaining UroGen Pharma position as of Q1 2020 after selling out during the quarter.
  • Horan Capital Advisors sold 1,000 UroGen Pharma shares in Q1 2020, an estimated $33K.
  • Horan Capital Advisors first reported a position in UroGen Pharma in Q3 2019 and held it in 2 quarters.
  • Horan Capital Advisors's UroGen Pharma position peaked at $33K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2020.

Based on Horan Capital Advisors's 13F filing for Q1 2020, filed 29 Apr 2020.